Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Legend Biotech $487 million IPO
Davis Polk advised the underwriters in connection with the $487 million SEC-registered initial public offering by Legend…
Humanigen $72 million stock PIPE offering
Davis Polk advised the placement agent in connection with a private placement pursuant to Rule 4(a)(2) by Humanigen Inc…
Atara Biotherapeutics $175 million stock and pre-funded warrants offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with a $175…
NuVasive $400 million convertible senior notes offering
Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NuVasive,…
Penumbra $143.75 million follow-on offering
Davis Polk advised Penumbra, Inc. on its SEC-registered follow-on public offering of 865,963 shares of common stock for an…
1Life Healthcare $275 million convertible senior notes offering
Davis Polk advised the joint book-running managers and representatives of the initial purchasers in connection with a…
TransMedics Group $70 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $70 million follow-on public offering…
DENTSPLY SIRONA $750 million notes offering
Davis Polk advised the representatives of the several underwriters in connection with an SEC-registered offering by…
Gamida Cell $60 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $60 million SEC-registered follow-on…
Turning Point Therapeutics $325 million stock offering
Davis Polk advised the joint book-running managers in connection with a $325 million SEC-registered common stock…